Allakos (NASDAQ:ALLK) Earns Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Allakos (NASDAQ:ALLK) in a report issued on Thursday, Benzinga reports.

Allakos Stock Down 8.0 %

Shares of ALLK opened at $1.03 on Thursday. The company’s fifty day moving average is $1.20 and its 200-day moving average is $1.60. Allakos has a 12 month low of $0.98 and a 12 month high of $5.64. The firm has a market cap of $91.20 million, a price-to-earnings ratio of -0.42 and a beta of 0.93.

Allakos (NASDAQ:ALLK) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.09). As a group, research analysts predict that Allakos will post -1.24 earnings per share for the current fiscal year.

Institutional Trading of Allakos

Several large investors have recently modified their holdings of ALLK. Blackstone Inc. boosted its holdings in shares of Allakos by 104.2% during the 3rd quarter. Blackstone Inc. now owns 4,096,652 shares of the company’s stock worth $9,299,000 after buying an additional 2,090,594 shares during the period. Sectoral Asset Management Inc. boosted its holdings in Allakos by 77.3% in the 3rd quarter. Sectoral Asset Management Inc. now owns 770,132 shares of the company’s stock valued at $1,748,000 after purchasing an additional 335,822 shares during the period. Redmile Group LLC boosted its holdings in Allakos by 81.1% in the 3rd quarter. Redmile Group LLC now owns 4,135,061 shares of the company’s stock valued at $9,387,000 after purchasing an additional 1,851,467 shares during the period. Aristides Capital LLC bought a new stake in Allakos in the 4th quarter valued at $153,000. Finally, Pennant Investors LP bought a new stake in Allakos in the 4th quarter valued at $508,000. 84.64% of the stock is owned by institutional investors.

About Allakos

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.